It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040,and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time. About 5% to 10% diabetic retinopathy would develop vision-threatening complications, including proliferative diabetic retinopathy (PDR), capillary non-perfusion, or macular edema. Data from the DRS suggest that given long enough duration of diabetes, approximately 60% of patients with DR will develop PDR, and without intervention, 75% nonproliferative diabetic retinopathy (NPDR) will development PDR within 1 year follow up, 45% will develop high-risk PDR, nearly half of PDR will experience profound visual loss. panretinal photocoagulation (PRP) only reduced 50% risk of sever visual loss and about 25% of the sNPDR patients who finished PRP need Pars-plana vitrectomy (PPV) in a 5 year follow up. Vitreous have been proven to play an important role in the development of NPDR to PDR, which were the collection of vascular endothelial growth factor (VEGF) factors and the major component of proliferative lesion in the later stage of PDR. Micro-invasive Pars-plana vitrectomy has been shown as a safe and effective method in the treatment of PDR, through removing the pathological vitreous, proliferative membrane and also the VEGF factors. However, whether or not Micro-invasive Pars-plana vitrectomy will be more effective than PRP to control the progression of NDPR remained unknown.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
272
Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China
RECRUITINGprogression rate of severe non proliferative diabetic retinopathy
the number of patients with severe non proliferative diabetic retinopathy progressed to proliferative diabetic retinopathy in each group from the baseline to 12 months
Time frame: 12 months
the change of best corrected visual acuity
The mean change in best corrected visual acuity in each group from baseline to 12 months
Time frame: 12 months
the rate of re-treatment
The number of patients who need re-treatment including supplement laser or vitrectomy from baseline to 12 months
Time frame: 12 months
The occurrence of diabetic macular edema
The occurrence number of diabetic macular edema in each group from baseline to 12 months
Time frame: 12 months
The change of central retinal thickness
the change of central retinal thickness from baseline to 12 months
Time frame: 12 months
The change of visual field
the change of visual field from baseline to 12 months
Time frame: 12 months
The occurrence of cataract
the occurrence of cataract from baseline to 12 months
Time frame: 12 months
The change of quality of life
the change of quality of life as assessed by questionnaire at 12 months
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.